Nuzenio

Radioligand Therapy

Radioligand Therapy news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 7 publisher sources 100/100 entity strength

Latest news

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMT Multidisciplinary Co-Management of Patients Receiving Radioligand Therapy - Phillip Koo & Neha Vapiwala - UroTodayUroToday · Fri, 07 Aug 2026 22:29:26 GMT Florida Theranostics: Advanced Imaging & Precision Radioligand Therapies with Dr. Ashok Muthu Krishn - WFLXWFLX · Fri, 07 Aug 2026 18:59:09 GMT FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed CareThe American Journal of Managed Care · Mon, 03 Aug 2026 17:37:08 GMT Pluvicto Approved Earlier in Metastatic Prostate Cancer - MedscapeMedscape · Mon, 03 Aug 2026 14:03:57 GMT Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 12:33:04 GMT AACR Special Conference in Cancer Research: Cancer Biology-informed Radioligand Therapy - OncodailyOncodaily · Sun, 02 Aug 2026 15:31:42 GMT Louise Emmett։ OPTIMAL-PSMA Trial Explores Dose-Intensified PSMA Radioligand Therapy - OncodailyOncodaily · Tue, 28 Jul 2026 07:00:00 GMT

Timeline

Sat, 08 Aug 2026 12:24:46 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - Novartis

Fri, 07 Aug 2026 22:29:26 GMTMultidisciplinary Co-Management of Patients Receiving Radioligand Therapy - Phillip Koo & Neha Vapiwala - UroToday

Fri, 07 Aug 2026 18:59:09 GMTFlorida Theranostics: Advanced Imaging & Precision Radioligand Therapies with Dr. Ashok Muthu Krishn - WFLX

Mon, 03 Aug 2026 17:37:08 GMTFDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed Care

Mon, 03 Aug 2026 14:03:57 GMTPluvicto Approved Earlier in Metastatic Prostate Cancer - Medscape

Mon, 03 Aug 2026 12:33:04 GMTNovartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer - Fierce Pharma

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.

Connected entities

Pluvicto4 live mentions Therapy3 live mentions Earlier3 live mentions PSMA2 live mentions Management2 live mentions Patients Receiving Radioligand2 live mentions Phillip Koo2 live mentions Advanced Imaging2 live mentions Precision Radioligand Therapies2 live mentions Ashok Muthu Krishn2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Radioligand Therapy.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.